- Home
- IRS vs ELVN Comparison
IRS vs ELVN Comparison
Compare IRS & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRS
- ELVN
- Stock Information
- Founded
- IRS 1943
- ELVN 2016
- Country
- IRS Argentina
- ELVN United States
- Employees
- IRS N/A
- ELVN N/A
- Industry
- IRS Homebuilding
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- IRS Real Estate
- ELVN Health Care
- Exchange
- IRS Nasdaq
- ELVN Nasdaq
- Market Cap
- IRS 1.2B
- ELVN 1.1B
- IPO Year
- IRS 1994
- ELVN 2020
- Fundamental
- Price
- IRS $16.03
- ELVN $24.24
- Analyst Decision
- IRS Strong Buy
- ELVN Strong Buy
- Analyst Count
- IRS 1
- ELVN 5
- Target Price
- IRS $12.62
- ELVN $37.80
- AVG Volume (30 Days)
- IRS 248.5K
- ELVN 164.8K
- Earning Date
- IRS 02-03-2025
- ELVN 11-13-2024
- Dividend Yield
- IRS 9.80%
- ELVN N/A
- EPS Growth
- IRS N/A
- ELVN N/A
- EPS
- IRS N/A
- ELVN N/A
- Revenue
- IRS $370,002,935.00
- ELVN N/A
- Revenue This Year
- IRS N/A
- ELVN N/A
- Revenue Next Year
- IRS N/A
- ELVN N/A
- P/E Ratio
- IRS N/A
- ELVN N/A
- Revenue Growth
- IRS N/A
- ELVN N/A
- 52 Week Low
- IRS $7.32
- ELVN $10.90
- 52 Week High
- IRS $17.67
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- IRS 54.16
- ELVN 46.10
- Support Level
- IRS $16.30
- ELVN $22.92
- Resistance Level
- IRS $17.23
- ELVN $24.42
- Average True Range (ATR)
- IRS 0.78
- ELVN 1.46
- MACD
- IRS -0.19
- ELVN 0.08
- Stochastic Oscillator
- IRS 21.57
- ELVN 56.56
About IRS IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segment includes Shopping Malls; Offices; Sales and Developments; Hotels and others. It generates maximum revenue from the Shopping Malls segment. The Shopping Malls segment comprised of lease and service revenues related to rental of commercial space and other spaces in the shopping malls of the company.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.